TG Therapeutics, Inc. Files Definitive Proxy Statement
Ticker: TGTX · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1001316
Sentiment: neutral
Topics: DEF 14A, Proxy Statement, TG Therapeutics, Shareholder Meeting, Executive Compensation
TL;DR
<b>TG Therapeutics, Inc. has filed its Definitive Proxy Statement for the period ending June 14, 2024.</b>
AI Summary
TG THERAPEUTICS, INC. (TGTX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. TG Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 29, 2024. The filing covers the period ending June 14, 2024. The company was formerly known as Manhattan Pharmaceuticals Inc. and Atlantic Technology Ventures Inc. TG Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC 2834). The filing includes details on equity awards and their fair value adjustments over several fiscal years.
Why It Matters
For investors and stakeholders tracking TG THERAPEUTICS, INC., this filing contains several important signals. This DEF 14A filing provides crucial information for shareholders regarding upcoming votes, executive compensation, and corporate governance matters. Shareholders should review this document to make informed decisions on proposals presented at the company's annual meeting.
Risk Assessment
Risk Level: low — TG THERAPEUTICS, INC. shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate governance procedures rather than immediate financial or operational distress.
Analyst Insight
Shareholders should review the proxy statement for details on executive compensation and voting proposals.
Key Numbers
- 2024-04-29 — Filing Date (DEF 14A filing date)
- 2024-06-14 — Period of Report (Conformed period of report)
- 2023-12-31 — Fiscal Year End (Company fiscal year end)
Key Players & Entities
- TG THERAPEUTICS, INC. (company) — Filer name
- DEF 14A (filing) — Form type
- 2024-04-29 (date) — Filing date
- 2024-06-14 (date) — Reporting period end date
- MANHATTAN PHARMACEUTICALS INC (company) — Former company name
- ATLANTIC TECHNOLOGY VENTURES INC (company) — Former company name
- 2 GANSEVOORT STREET, 9TH FLOOR (address) — Business address
- NEW YORK (location) — Business address city
FAQ
When did TG THERAPEUTICS, INC. file this DEF 14A?
TG THERAPEUTICS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by TG THERAPEUTICS, INC. (TGTX).
Where can I read the original DEF 14A filing from TG THERAPEUTICS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by TG THERAPEUTICS, INC..
What are the key takeaways from TG THERAPEUTICS, INC.'s DEF 14A?
TG THERAPEUTICS, INC. filed this DEF 14A on April 29, 2024. Key takeaways: TG Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on April 29, 2024.. The filing covers the period ending June 14, 2024.. The company was formerly known as Manhattan Pharmaceuticals Inc. and Atlantic Technology Ventures Inc..
Is TG THERAPEUTICS, INC. a risky investment based on this filing?
Based on this DEF 14A, TG THERAPEUTICS, INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating standard corporate governance procedures rather than immediate financial or operational distress.
What should investors do after reading TG THERAPEUTICS, INC.'s DEF 14A?
Shareholders should review the proxy statement for details on executive compensation and voting proposals. The overall sentiment from this filing is neutral.
How does TG THERAPEUTICS, INC. compare to its industry peers?
TG Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, focusing on the development of treatments.
Are there regulatory concerns for TG THERAPEUTICS, INC.?
As a public company, TG Therapeutics, Inc. is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.
Industry Context
TG Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, focusing on the development of treatments.
Regulatory Implications
As a public company, TG Therapeutics, Inc. is subject to SEC regulations, including the requirement to file proxy statements for shareholder meetings.
What Investors Should Do
- Review executive compensation details within the proxy statement.
- Understand the proposals to be voted on at the shareholder meeting.
- Assess any changes in corporate governance practices outlined in the filing.
Key Dates
- 2024-04-29: Filing of DEF 14A — Provides shareholder information for the upcoming meeting.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a standard disclosure for public companies regarding their annual meetings and executive compensation, not a comparison to a prior period's financial performance.
Filing Stats: 4,800 words · 19 min read · ~16 pages · Grade level 12.1 · Accepted 2024-04-29 16:32:56
Key Financial Figures
- $0.001 — rized shares of common stock, par value $0.001 per share ("Common Stock") from 175,000
Filing Documents
- tgtx20240423_def14a.htm (DEF 14A) — 914KB
- capvsnetincomesmall.jpg (GRAPHIC) — 35KB
- p01.jpg (GRAPHIC) — 232KB
- p02.jpg (GRAPHIC) — 205KB
- picture1capvstsrsmall.jpg (GRAPHIC) — 36KB
- picture5capvscsfmsmall.jpg (GRAPHIC) — 34KB
- tgtxlogo01.jpg (GRAPHIC) — 6KB
- 0001437749-24-013719.txt ( ) — 3049KB
- tgtx-20231231.xsd (EX-101.SCH) — 3KB
- tgtx-20231231_def.xml (EX-101.DEF) — 2KB
- tgtx-20231231_lab.xml (EX-101.LAB) — 2KB
- tgtx-20231231_pre.xml (EX-101.PRE) — 1KB
- tgtx20240423_def14a_htm.xml (XML) — 198KB
Executive Compensation
Executive Compensation 23 Summary Compensation Table 23 Grants of Plan-Based Awards For Fiscal Year 2023 24 Outstanding Equity Awards at 2023 Fiscal Year End 25 Stock Vested in Fiscal Year 2023 26 Employment Agreements 26 Potential Payments upon Termination or Change in Control 28 CEO Pay Ratio 29 Pay Versus Performance 30 Director Compensation 33 2023 Director Compensation 33 Compensation Committee Interlocks and Insider Participation 34 Related-Person Transactions 35 Stock Ownership of Our Directors, Executive Officers, and 5% Beneficial Owners 36 Proposal One: Election of Directors Nominees 37 Proposal Two: Ratification of Appointment of KPMG LLP as Our Independent Registered Public Accounting Firm 38 Proposal Three: Advisory Vote to Approve the Compensation of Our Named Executive Officers 39 Proposal Four: Approval of the Amendment to our Certificate of Incorporation 40 Proposal Five : Approval of the Amendment to our 2022 Incentive Plan 42 Additional Information 48 Appendix A 49 Appendix B 50 Table of Contents QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING Q : Why did I receive an " Important Notice Regarding the Availability of Proxy Materials? " A. In accordance with Securities and Exchange Commission ("SEC") rules, instead of mailing a printed copy of our proxy materials, we may send an "Important Notice Regarding the Availability of Proxy Materials" to stockholders. All stockholders will have the ability to access the proxy materials on a website referred to in the notice or to request a printed set of these materials at no charge. You will not receive a printed copy of the proxy materials unless you specifically request one from us. Instead, the notice instructs you as to how you may access and review all of the important information contained in the proxy materials via the internet and submit your vote via the internet. Q: When is the Annual Meeting?